Truvada Growth Driven By Placement On First-Line Regimens, Gilead Says
This article was originally published in The Pink Sheet Daily
Truvada (emtricitabine/tenofovir disoproxil) brand awareness is close to 100% among HIV treatment community partly due to direct-to-consumer ads, which will continue throughout 2005, Gilead says. Most growth comes from treatment-naive patients, followed by Viread and Emtriva switches, firm says.
You may also be interested in...
Bristol-Myers Squibb and Gilead are developing a "back-up" formulation of the fixed-dose combination of Sustiva and Truvada that is the subject of their joint venture
The approvals of Gilead’s Truvada and GSK’s Epzicom were announced publicly by FDA Acting Commissioner Crawford during a Washington, D.C. luncheon speech. Gilead is shipping Truvada to wholesalers this week. Two month supplies of Epzicom will be available free to patients through participating physicians for a limited time.
Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.